Form 4: Director Aoife Brennan Receives Xilio Therapeutics Options

Director Aoife Brennan was granted 5,000 stock options in Xilio Therapeutics, Inc. as part of a standard equity compensation package.

Summary

• Director Aoife Brennan received a grant of 5,000 stock options for Xilio Therapeutics, Inc. (XLO) common stock.
• The options have an exercise price of $7.99 per share.
• The grant date for these options is June 11, 2026.
• The options are scheduled to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Xilio Therapeutics common stock.

Future Outlook

The options vest 100% on the earlier of June 11, 2027, or the date of the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard director compensation packages for small-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on June 11, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Xilio Therapeutics, XLO, Form 4, Director Compensation, Stock Options, Insider Trading